Cosciens Biopharma Inc (CSCI)

$3.22 +0.07 (2.22%)
Market Cap 9.89M
Revenue (ttm) 9.59M
Net Income (ttm) -15.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -159.65%
Debt to Equity Ratio 0.00
Volume 2,500
Avg Vol 27,466
Day's Range N/A - N/A
Shares Out 3.14M
Stochastic %K 100%
Beta 1.27
Analysts Strong Buy
Price Target N/A

Latest News on CSCI

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Apr 9, 2025, 5:00 PM EDT - 16 days ago

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

Apr 1, 2025, 7:25 PM EDT - 24 days ago

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

Mar 19, 2025, 7:32 PM EDT - 5 weeks ago

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

Mar 13, 2025, 7:55 AM EDT - 6 weeks ago

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

Dec 23, 2024, 7:45 AM EST - 4 months ago

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

Nov 12, 2024, 7:30 AM EST - 5 months ago

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

COSCIENS Biopharma Announces Change to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 7 months ago

COSCIENS Biopharma Announces Change to Board of Directors

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

Oct 1, 2024, 5:30 PM EDT - 7 months ago

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

Sep 23, 2024, 7:30 AM EDT - 7 months ago

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Aug 27, 2024, 7:30 AM EDT - 8 months ago

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 8:05 AM EDT - 9 months ago

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results